Phase 3 N=20 The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
Allergic Contact Dermatitis
Primary: Clinical Reaction — 0; 0; 12; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 2 N=12 Study of Apremilast in Atopic or Contact Dermatitis
Atopic Dermatitis · Allergic Contact Dermatitis
Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants
N/A N=42 Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis
Hand Dermatosis
Primary: Investigator Global Assessment — 1.0; 1.1 units on a scale
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
Phase 4 N=20 A Study for a Topical Medication Versus Placebo in Patients With Hand Dermatitis
Hand Dermatitis
Primary: Primary Outcome Measure for Efficacy (IGA) — 2.33; 2.20; 2.43; 2 score on a scale
N/A N=50 Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
Allergic Contact Dermatitis
Primary: Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0) — 14.53; 16.03; 109.1; 110.7 pg/ml
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Phase 3 N=235 Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
Contact Dermatitis
Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
Phase 2 N=48 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 4 N=30 Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
Hand Dermatosis
Primary: Proportion of Subjects With at Least 1-grade Improvement From Baseline to Day 15 in Investigator's Static Global Assessment Score (ISGA) Score — 96.7 Percentage of…
N/A N=36 Patch Test of Benzalkonium Chloride Disinfectant Spray
Wound Healing
Primary: Proportion of Participants With Skin Irritation Scores at 24 Hours — 75.0; 91.7; 94.4; 94.4 Percentage of participants
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Dermal Irritation
Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants
Phase 1 N=46 A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Healthy
Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001
N/A N=80 A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
Dermatitis, Contact
Primary: Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit — 93.8; 6.30 Percentage of Participants
N/A N=110 Skin Prick Test of KeraStat® Cream
Hypersensitivity
Primary: Reaction to Test Article — 0; 0.32; 0.23; 6.73 mm
Phase 2 N=16 Topical Ruxolitinib in Chronic Hand Dermatitis
Chronic Hand Dermatitis
Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants
Phase 2 N=22 Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis
Dermatitis, Allergic Contact
Primary: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 — 5; 9 Participants
Phase 3 N=686 Oral Curcumin for Radiation Dermatitis
Radiation-induced Dermatitis
Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555
N/A N=25 Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=9 Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Phase 1 N=234 A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
Healthy
Primary: Observed Sensitization — 0; 0; 0 Participants with Observed Sensitization
Phase 2 N=63 Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change in EASI From Baseline at Day 29 — -47.37; -42.10 percent change
Phase 3 N=39 Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth
Surgery
Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)
Phase 1 N=58 Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Photoallergy
Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…